• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Immunohistochemical Diversity of Endometrial Carcinoma and Their Implications in Prognosis: A Prospective Clinicopathological Study in a Tertiary Care Hospital of Eastern India.子宫内膜癌的免疫组织化学多样性及其对预后的影响:印度东部一家三级护理医院的前瞻性临床病理研究
J Obstet Gynaecol India. 2025 Apr;75(Suppl 1):166-172. doi: 10.1007/s13224-024-02046-9. Epub 2024 Aug 31.
2
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
3
Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.子宫内膜样型子宫内膜癌 2 级 IA 期(FIGO)患者的保留生育力方法:定性系统评价。
Biomed Res Int. 2022 Sep 27;2022:4070368. doi: 10.1155/2022/4070368. eCollection 2022.
4
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂(GLP-1 RAs)减肥效果的网状Meta分析的数量、质量及结果:一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
7
Immunohistochemical Staining: Prognostic Marker of Malignant Transformation of Hydatidiform Mole (HM).免疫组织化学染色:葡萄胎(HM)恶性转化的预后标志物。
J Obstet Gynaecol India. 2025 Apr;75(Suppl 1):365-370. doi: 10.1007/s13224-024-02002-7. Epub 2024 Jul 23.
8
Lymphadenectomy or sentinel node biopsy for the management of endometrial cancer.用于子宫内膜癌治疗的淋巴结切除术或前哨淋巴结活检术。
Cochrane Database Syst Rev. 2025 Jun 10;6(6):CD015786. doi: 10.1002/14651858.CD015786.pub2.
9
Hormone replacement therapy for women previously treated for endometrial cancer.曾接受子宫内膜癌治疗的女性的激素替代疗法。
Cochrane Database Syst Rev. 2018 May 15;5(5):CD008830. doi: 10.1002/14651858.CD008830.pub3.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

本文引用的文献

1
Estrogen Receptor (ER) and Progesterone Receptor (PgR) Expression in Endometrial Cancer-An Immunohistochemical Assessment.子宫内膜癌中雌激素受体(ER)和孕激素受体(PgR)的表达——一项免疫组织化学评估
Diagnostics (Basel). 2024 Feb 1;14(3):322. doi: 10.3390/diagnostics14030322.
2
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.子宫肿瘤,第1.2023版,美国国立综合癌症网络(NCCN)肿瘤学临床实践指南
J Natl Compr Canc Netw. 2023 Feb;21(2):181-209. doi: 10.6004/jnccn.2023.0006.
3
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.泛亚地区适应性欧洲肿瘤内科学会(ESMO)子宫内膜癌诊断、治疗和随访临床实践指南。
ESMO Open. 2023 Feb;8(1):100774. doi: 10.1016/j.esmoop.2022.100774. Epub 2023 Jan 23.
4
Cytokeratin Expression Pattern in Human Endometrial Carcinomas and Lymph Nodes Micrometastasis: a Mini-review.人子宫内膜癌和淋巴结微转移中的细胞角蛋白表达模式:一篇综述
J Cancer. 2022 Mar 14;13(6):1713-1724. doi: 10.7150/jca.70550. eCollection 2022.
5
British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice.英国妇科癌症协会(BGCS)子宫癌指南:实践建议。
Eur J Obstet Gynecol Reprod Biol. 2022 Mar;270:50-89. doi: 10.1016/j.ejogrb.2021.11.423. Epub 2021 Nov 25.
6
Cancer of the corpus uteri: 2021 update.子宫体癌:2021年更新
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):45-60. doi: 10.1002/ijgo.13866.
7
The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions.TCGA子宫内膜癌分子分类及其对辅助治疗决策的潜在影响。
Cancers (Basel). 2021 Mar 23;13(6):1478. doi: 10.3390/cancers13061478.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.ESGO/ESTRO/ESP 子宫内膜癌管理指南。
Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.
10
HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes.高危子宫内膜癌中的HER2状态(PORTEC-3):与组织类型、分子分类及临床结局的关系
Cancers (Basel). 2020 Dec 25;13(1):44. doi: 10.3390/cancers13010044.

子宫内膜癌的免疫组织化学多样性及其对预后的影响:印度东部一家三级护理医院的前瞻性临床病理研究

Immunohistochemical Diversity of Endometrial Carcinoma and Their Implications in Prognosis: A Prospective Clinicopathological Study in a Tertiary Care Hospital of Eastern India.

作者信息

Pradhan Rajashree, Roy Biswas Ranu, Mondal Sajeeb, Mukherjee Upasana

机构信息

Department of Pathology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal India.

Department of Pathology, Medical College Kolkata, Kolkata, West Bengal India.

出版信息

J Obstet Gynaecol India. 2025 Apr;75(Suppl 1):166-172. doi: 10.1007/s13224-024-02046-9. Epub 2024 Aug 31.

DOI:10.1007/s13224-024-02046-9
PMID:40390967
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12085500/
Abstract

BACKGROUND

Endometrial cancer is the sixth most common cancer in women worldwide with gradually increasing incidence and mortality rate. The most recent classification of endometrial carcinoma (EC) with diagnostic flowchart includes both immunohistochemical and molecular markers for prognostic purpose and better management of endometrial cancer. In this study, we want to analyze various immunohistochemical (IHC) markers in EC and their prognostic significance.

METHODS

This was a prospective study conducted from August 2016 to February 2024. We studied 168 cases of EC for histopathological subtypes, grading and various IHC markers such as Estrogen Receptor (ER), Her 2 Neu, Cytokeratin 5/6, Epithelial Membrane Antigen (EMA) and p53.

RESULTS

In our study, most common histological subtype was endometrioid (132) followed by serous (17), mucinous (8), clear cell (7) and carcinosarcoma (4). ER expression was mostly seen in endometrioid type. Loss of ER expression and Her 2 expression along with p53 over expression was not only associated with high grade EC but also with advanced clinical stage and lymph node metastasis.

CONCLUSION

Immunohistochemical markers play a definite role in risk stratification and specific individual oriented therapy in endometrial cancer patients.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s13224-024-02046-9.

摘要

背景

子宫内膜癌是全球女性中第六大常见癌症,其发病率和死亡率呈逐渐上升趋势。子宫内膜癌(EC)的最新分类及诊断流程图包括用于预后目的和更好管理子宫内膜癌的免疫组织化学和分子标志物。在本研究中,我们想要分析EC中的各种免疫组织化学(IHC)标志物及其预后意义。

方法

这是一项于2016年8月至2024年2月进行的前瞻性研究。我们研究了168例EC病例的组织病理学亚型、分级以及各种IHC标志物,如雌激素受体(ER)、人表皮生长因子受体2(Her 2 Neu)、细胞角蛋白5/6、上皮膜抗原(EMA)和p53。

结果

在我们的研究中,最常见的组织学亚型是子宫内膜样癌(132例),其次是浆液性癌(17例)、黏液性癌(8例)、透明细胞癌(7例)和癌肉瘤(4例)。ER表达多见于子宫内膜样癌类型。ER表达缺失、Her 2表达以及p53过表达不仅与高级别EC相关,还与晚期临床分期和淋巴结转移相关。

结论

免疫组织化学标志物在子宫内膜癌患者的风险分层和个体化治疗中发挥着明确作用。

补充信息

在线版本包含可在10.1007/s13224-024-02046-9获取的补充材料。